NCT06192017 is a clinical trial of WomEC in Endometrium Cancer, sponsored by MiMARK Diagnostics, S.L..

Who is sponsoring NCT06192017?

NCT06192017 is sponsored by MiMARK Diagnostics, S.L..

What drugs are being tested in NCT06192017?

Interventions in NCT06192017: WomEC.

What condition does NCT06192017 study?

NCT06192017 studies Endometrium Cancer.

Is NCT06192017 still recruiting?

NCT06192017 is currently completed. Last updated 28 August 2025.

Last reviewed 2025-08-28 · How we verify

NCT06192017

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Development of a Molecular Diagnostic Tool for Endometrial Cancer.

Completed Last updated 28 August 2025

What this trial tests

trial testing WomEC in Endometrium Cancer in 1,950 participants. Completed in 31 July 2025.

Timeline

18 October 2023

Primary endpoint
31 July 2025

31 July 2025

Quick facts

Lead sponsor	MiMARK Diagnostics, S.L.
Status	Completed
Study type	OBSERVATIONAL
Enrollment	1,950
Start date	18 October 2023
Primary completion	31 July 2025
Estimated completion	31 July 2025
Sites	26 locations across Spain

Drugs / interventions tested

WomEC

Conditions studied

Endometrium Cancer — all drugs for Endometrium Cancer →

Sponsor

MiMARK Diagnostics, S.L.

Who can join

18 and older, female only, with Endometrium Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

WomEC is an in vitro diagnostic test for Endometrial Cancer (EC) based on the detection of the expression level of a combination of 5 proteins in the soluble fraction of a pipelle biopsy specimen. The aim of the study consists in validating WomEC's ELISA test, creating and freezing an algorithm to rule out EC in post-menopausal women with abnormal uterine bleeding (AUB).

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Endometrium Cancer

Currently open trials in the same condition.

NCT07503808 — A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types · Phase 1 · recruiting
NCT07318727 — Comparative Study on the Effect of Diet Interventions on Weight Loss in Overweight Endometrial Cancer Patients Undergoin · NA · recruiting
NCT06841653 — A.I and Machine Learning Based Risk Prediction Model to Improve the Clinical Management of Endometrial Cancer. · recruiting
NCT06169449 — Weight Management in Overweight Endometrial Cancer Patients Undergoing Fertility-sparing Treatment · NA · recruiting
NCT04014530 — Pembrolizumab With Ataluren in Patients With Metastatic pMMR and dMMR Colorectal Carcinoma or Metastatic dMMR Endometria · Phase 1, PHASE2 · recruiting

Other MiMARK Diagnostics, S.L. trials

Trials by the same sponsor.

NCT07148154 — Development of a Non-invasive IVD for Endometrial Cancer Screening on High-risk Populations · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06192017 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by MiMARK Diagnostics, S.L.
Last refreshed: 28 August 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06192017.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing